Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)
NCT ID: NCT00617019
Last Updated: 2013-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3234 participants
OBSERVATIONAL
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parkinson's patients
Observational study to compare rates of impulse control disorders in patients taking different medications for Parkinson's Disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Male or female outpatients, aged 30 to 75 years of age, with idiopathic PD. Patients must be selected on the basis of a prospective recruitment plan documented at the site, with the objective of obtaining an unbiased representative sample.
Patients must have been treated with anti-parkinson medication for a period of one year or greater and demonstrated a treatment response, in the opinion of the Investigator.
Patients must be willing and able to comply with study procedures. Patients must be willing and able to give meaningful, written informed consent. This must be completed prior to beginning any study procedures, in accordance with GCP and local legislation.
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Boehringer Ingelheim
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
248.619.01034 Neurological Physicians of Arizona
Gilbert, Arizona, United States
248.619.01007 Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States
248.619.01025 Sun Health Research Institute
Sun City, Arizona, United States
248.619.01018 Margolin Brain Institute
Fresno, California, United States
248.619.01031 Pacific Neuroscience Medical Group, Inc.
Oxnard, California, United States
248.619.01016 San Francisco VA PD Research, Education, & Clinical Center
San Francisco, California, United States
248.619.01023 The Parkinson's Institute
Sunnyvale, California, United States
248.619.01021 Boehringer Ingelheim Investigational Site
Englewood, Colorado, United States
248.619.01027 Associated Neurologists, P.C.
Danbury, Connecticut, United States
248.619.01013 Molecular NeuroImaging
New Haven, Connecticut, United States
248.619.01020 Parkinson's Disease and Movement Disorders of Boca Raton
Boca Raton, Florida, United States
248.619.01009 University of Florida
Gainesville, Florida, United States
248.619.01035 Emory University
Atlanta, Georgia, United States
248.619.01006 Medical College of Georgia
Augusta, Georgia, United States
248.619.01014 Northwestern University
Chicago, Illinois, United States
248.619.01001 The University of Kansas Medical Center
Kansas City, Kansas, United States
248.619.01015 John Hopkins Hospital
Baltimore, Maryland, United States
248.619.01029 Clinical Neuroscience Center
Southfield, Michigan, United States
248.619.01022 University of Minnesota
Minneapolis, Minnesota, United States
248.619.01008 Robert Wood Johnson Medical School
Piscataway, New Jersey, United States
248.619.01030 Parkinson's Disease and Movement Disorders Center
Albany, New York, United States
248.619.01036 Parkinson's Disease and Mov. Disorders Center of Long Island
Commack, New York, United States
248.619.01017 Weill Cornell medical College
New York, New York, United States
248.619.01003 Duke University Medical Center
Durham, North Carolina, United States
248.619.01028 The Cleveland Clinic Foundation
Cleveland, Ohio, United States
248.619.01004 Lehigh Valley Hospital
Allentown, Pennsylvania, United States
248.619.01010 Parkinson's Disease research, Education and Clinical Center
Philadelphia, Pennsylvania, United States
248.619.01011 University of Pennsylvania
Philadelphia, Pennsylvania, United States
248.619.01024 Thomas Jefferson Hospital
Philadelphia, Pennsylvania, United States
248.619.01019 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
248.619.01012 Parkinson's Disease and Movement Disorders Center
Upland, Pennsylvania, United States
248.619.01005 NeuroHealth
Warwick, Rhode Island, United States
248.619.01033 Vanderbilt University Medical Center
Nashville, Tennessee, United States
248.619.01032 Neurology Spclst of Dallas, PA
Dallas, Texas, United States
248.619.01002 Baylor College of Medicine
Houston, Texas, United States
248.619.01026 Neurology/Southeast Parkinson's Disease
Richmond, Virginia, United States
248.619.02011 University of Calgary
Calgary, Alberta, Canada
248.619.02010 The Glenrose Rehab. Hospital
Edmonton, Alberta, Canada
248.619.02009 Movement Disorder Clinic
Winnipeg, Manitoba, Canada
248.619.02005 Health Sciences Centre
St. John's, Newfoundland and Labrador, Canada
248.619.02019 Dr. David King
Halifax, Nova Scotia, Canada
248.619.02013
Kitchener, Ontario, Canada
248.619.02018 London HSC - University Hospital
London, Ontario, Canada
248.619.02001 Centre for Movement Discorder
Markham, Ontario, Canada
248.619.02008 Ottawa Civic Hospital
Ottawa, Ontario, Canada
248.619.02016 The Toronto Western Hospital
Toronto, Ontario, Canada
248.619.02003 Unite des Troubles du Mouvement
Montreal, Quebec, Canada
248.619.02002 Memory and Motor Skills Disorders Clinic
Québec, Quebec, Canada
248.619.02017 Royal University Hospital
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010 May;67(5):589-95. doi: 10.1001/archneurol.2010.65.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DOMINION
Identifier Type: -
Identifier Source: secondary_id
248.619
Identifier Type: -
Identifier Source: org_study_id